QR kód

Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials

BackgroundRelapsing multiple sclerosis (RMS) is a chronic, inflammatory disease of the central nervous system. Ublituximab, an anti-CD20 monoclonal antibody (mAb), is indicated for the treatment of RMS. We performed a systematic literature review (SLR) to identify randomized trials reporting the cli...

Celý popis

Uloženo v:
Hlavní autoři: Eoin Moloney, Atefeh Mashayekhi, Sakshi Sharma, Vasileios Kontogiannis, Amir Ansaripour, Wallace Brownlee, David Paling, Mehdi Javanbakht
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2024-12-01
Edice:Frontiers in Neurology
Témata:
relapsing multiple sclerosis
relapsing-remitting
secondary progressive
monoclonal antibodies
ublituximab
systematic review
On-line přístup:https://www.frontiersin.org/articles/10.3389/fneur.2024.1479476/full
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky